Role of Ivermectin and Colchicine in Treating COVID-19
Objective
This study aimed to evaluate how effective ivermectin and colchicine are as treatments for COVID-19.
Methodology
A clinical trial was conducted with three groups at Ain Shams University Hospitals. Participants with moderate COVID-19 were included, while those under 18, over 65, or with other health issues were excluded. Randomization was done using sealed envelopes, and patients were monitored for symptom improvement for over a month.
Results
A total of 120 patients participated in the study, with similar numbers in each treatment group. The main symptoms were fever and cough. The study found:
- There was no significant difference in the duration of fever among the groups.
- About 67.5% to 72.5% of patients recovered completely within 10 days, with no differences noted between treatment methods.
- Inflammatory markers improved for all groups over time, but again, no significant differences were observed.
Conclusions
Ivermectin and colchicine did not provide any additional benefits over standard care for treating COVID-19.
Value of Clinical Trials
Clinical trials are essential for finding safe and effective treatments. Tools like DocSym, our AI-driven platform, help integrate clinical guidelines and research into everyday practices, making it easier for healthcare professionals to access important information.
Enhancing Healthcare Delivery
In today’s healthcare landscape, improving operations is critical. Our mobile apps facilitate patient scheduling, treatment monitoring, and telemedicine, streamlining care management.
AI in Clinics
By using AI, clinics can optimize workflows, improve patient outcomes, and reduce reliance on paper systems. Discover how we can assist you at aidevmd.com.
